⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ROIV News
Roivant Sciences Ltd. Common Shares
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
globenewswire.com
ROIV
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
globenewswire.com
ABUS
ROIV
PFE
BNTX
MRNA
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight
globenewswire.com
IMVT
ROIV
MRK
NVS
REGN
UCB
JNJ
ARGX
AMGN
VIR
IPHA
ARWR
APLS
CABA
Form 8-K
sec.gov
ROIV
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
globenewswire.com
ROIV
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
globenewswire.com
IMVT
ROIV
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
globenewswire.com
ROIV
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
globenewswire.com
IMVT
ROIV
CART
NVS
MRK
REGN
UCB
JNJ
AMGN
ARGX
KYMR
CABA
BMY
BHVN
Form 8-K
sec.gov
ROIV
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
globenewswire.com
ROIV
ROIVW